Drug products: Ethosuximide Orifarm, Etosuximid 2care4, Etosuximid Abboxia, Etosuximid Ebb, Etosuximid Medartuum, Etosuximid Paranova, Petnidan, Suxinutin, Suxinutin®, Zarondan, Zarontin
ATC code: N03AD01
Randomized controlled trials of differences between men and women in effect and safety of ethosuximide are lacking. Women seem to have a lower clearance than men, a difference that varies depending on dose.
One study in patients treated with ethosuximide (20 boys/men, 26 girls/women; age 1.5-38 years) showed that plasma concentration increased more rapidly, relative to dose, in girls/women than in boys/men . Another study in young adults (12 men, 21 women), with half of the women on oral contraceptives, revealed a 27% lower clearance in women in general and no difference associated with use of oral contraceptives . No sex differentiation in dosing has been recommended by the pharmaceutical company .
No studies with a clinically relevant sex analysis regarding the effects of ethosuximide have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of ethosuximide have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2019-10-15
Reviewed by: Mia von Euler, Carl-Olav Stiller
Approved by: Karin Schenck-Gustafsson